Use of antidepressant medications to improve outcomes after stroke topical collection on stroke

Current Neurology and Neuroscience Reports

Volumn 13, Issue 1, 2013, Pages

  Chollet, F ^a   Acket, B ^a   Raposo, N ^a   Albucher, J F ^a   Loubinoux, I ^a   Pariente, J ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Antidepressants; Brain plasticity; Depression; Fluoxetine; Monoaminergic drugs; Motor function; Recovery; Stroke

Indexed keywords

ACETYLCHOLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE; FLUOXETINE; MAPROTILINE; METHYLPHENIDATE; MOCLOBEMIDE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN; TRAZODONE;

APHASIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG USE; FUNCTIONAL ASSESSMENT; HUMAN; MOTOR PERFORMANCE; NONHUMAN; OUTCOME ASSESSMENT; PHYSIOTHERAPY; SINGLE DRUG DOSE; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); DRUG EFFECT; MOTOR ACTIVITY; REVIEW;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; HUMANS; MOTOR ACTIVITY; RECOVERY OF FUNCTION; STROKE;

EID: 84873092658     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0318-z     Document Type: Article

References (50)

1. Loubinoux I, Chollet F. Neuropharmacology in stroke recovery. In: Cramer SC, Nudo RJ, editors. Brain repair after stroke. Cambridge: Cambridge University Press; 2010. p. 183-93.
2. Goldstein LB. Influence of common drugs and related factors on stroke outcome. Curr Opin Neurol. 1997;10:52-7. (Pubitemid 27136243)
3. Liepert J. Pharmacotherapy in restorative neurology. Current Opin Neurol. 2008;21:639-43.
4. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD003437. doi: 10.1002/14651858.CD003437.pub3.
5. Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22(3):159-66. (Pubitemid 46559872)
6. •• Salter K, Bhogal S, Teasell R, Foley N, Speechley M. Post-stroke depression. The evidence-based review of stroke rehabilitation (EBRSR) Version 15. http://www.ebrsr.com/uploads/Depression-SREBR-15-1.pdf. Exhaustive review of the relationships between stroke and depression.
7. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment and disease progression. Biol Psychiatry. 2003;54:376-87. (Pubitemid 37267864)
8. Farner L, Wagle J, Engedal K, Flekkoy KM, Wyller TB, Fure B. Depressive symptoms in stroke patients: a 13 month follow-up study of patients referred to a rehabilitation unit. J Affect Disord. 2010;127(1-3):211-8.
9. Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study. Stroke. 1993;24(7):976-82. (Pubitemid 23201453)
10. Berg A, Psych L, Palomaki H, et al. Poststroke depression - an 18-month follow-up. Stroke. 2003;34(1):138-43. (Pubitemid 36074938)
11. Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V. The Italian multicenter observational study on post-stroke depression (DESTRO). J Neurol. 2006;253:556-62. (Pubitemid 43876983)
12. Paolucci S, Gandolfo C, Provinciali L, Torta R, Sommacal S, Toso V. Quantification of the risk of post-stroke depression: the Italian multicenter observational study DESTRO. Acta Psychiatr Scand. 2005;112:272-8. (Pubitemid 41382733)
13. Hackett ML, Anderson CS. Frequency, management, and predictors of abnormal mood after stroke: the Auckland Regional Community Stroke (ARCOS) study, 2002 to 2003. Stroke. 2006;37:2123-8. (Pubitemid 44309914)
14. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. Stroke. 2005;36:2296-301. (Pubitemid 41429266)
15. Bour A, Rasquin S, Aben I, Boreas A, Limburg M, Verhey F. A one-year follow-up study into the course of depression after stroke. J Nutr Health Aging. 2010;14:488-93.
16. Carota A, Berney A, Aybek S, et al. A prospective study of predictors of poststroke depression. Neurology. 2005;64:428-33. (Pubitemid 40189858)
17. Goodwin RD, Devanand DP. Stroke, depression, and functional health outcomes among adults in the community. J Geriatr Psychiatry Neurol. 2008;21:41-6. (Pubitemid 351257760)
18. Van de Port I, Kwakkel G, van WI, Lindeman E. Susceptibility to deterioration of mobility long-term after stroke: a prospective cohort study. Stroke. 2006;37:167-71. (Pubitemid 43732067)
19. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351-9. (Pubitemid 30145919)
20. Finklestein SP, Weintraub RJ, Karmouz N, Askinazi C, Davar G, Baldessarini RJ. Antidepressant drug treatment for post stroke depression: retrospective study. Arch Phys Med Rehabil. 1987;68:772-6. (Pubitemid 17163671)
21. Lauritzen L, Bendsen BB, Vilmar T, Bendsen EB, Lunde M, Bech P. Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study. Psychopharmacology (Berl). 1994;114:119.
22. Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2008;20:178-84.
23. Kucukalic A, Bravo-Mehmedbasic A, Kulenovic AD, Suljic-Mehmedika E. Venlafaxine efficacy and tolerability in the treatment of post-stroke depression. Psychiatr Danub. 2007;19:56-60. (Pubitemid 47045671)
24. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovasc Dis. 2008;26(3):266-71.
25. Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke. 2006;37:156-61. (Pubitemid 43732065)
26. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early post-stroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829-32. (Pubitemid 30620458)
27. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression - a three-month double-blind placebo-controlled study with open-label long-term follow up. J Neurol. 2003;250:347-51. (Pubitemid 36399276)
28. Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a doubleblind, placebo-controlled study. Arch Phys Med Rehabil. 1998;79:1047-50. (Pubitemid 28419310)
29. Tardy J, Pariente J, Leger A, et al. Methylphenidate modulates cerebral post-stroke reorganization. Neuroimage. 2006;33:913-22. (Pubitemid 44584756)
30. Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr. 1995;7:547-60. (Pubitemid 26105909)
31. Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy and functional recovery. J Neurol Neurosurg Psychiatry. 2001;71:258-61. (Pubitemid 32675158)
32. Miyai I, Reding MJ. Effects of antidepressants on functional recovery following stroke: a double-blind study. J Neurol Rehabil. 1998;12:5-13. (Pubitemid 28213351)
33. Narushima K, Chan KL, Kosier JT, Robinson RG. Does cognitive recovery after treatment of poststroke depression last? A 2-year follow-up of cognitive function associated with poststroke depression. Am J Psychiatry. 2003;160:1157-62. (Pubitemid 41070976)
34. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211-4. (Pubitemid 26226957)
35. Schmid AA, Kroenke K, Hendrie HC, Bakas T, Sutherland JM, Williams LS. Poststroke depression and treatment effects on functional outcomes. Neurology. 2011;76(11):1000-5.
36. •• Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123-30. First trial demonstrating the positive effect of SSRI fluoxetine on motor deficit of patients with ischaemic stroke.
37. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009;256(7):1152-8.
38. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair. 2008;22:311-4. (Pubitemid 351561669)
39. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50:718-29. (Pubitemid 33116131)
40. Gerdelat-Mas A, Loubinoux I, Tombari D, et al. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage. 2005;27:314-22. (Pubitemid 41074834)
41. Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M, Robinson RG. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011.
42. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, Fonzetti P, Hegel M, Arndt S. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299(20):2391- 400. (Pubitemid 351749237)
43. Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD003689. doi: 10.1002/14651858.CD003689.pub3.
44. Narushima K, Kosier JT, Robinson RG. Preventing poststroke depression. A 12-week double-blind randomized treatment trail and 21-month follow-up. J Nerv Ment Dis. 2002;190:296-303. (Pubitemid 34533660)
45. Palomaki H, Kaste M, Berg A, Lonnqvist R, Lonnqvist J, Lehtihalmes M, Hares J. Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. J Neurol Neurosurg Psychiatry. 1999;66:490-4. (Pubitemid 29145685)
46. Zittel S, Weiller C, Liepert J. Reboxetine improves motor function in chronic stroke: A pilot study. J Neurol. 2007;254:197-201. (Pubitemid 46356052)
47. Laska AC, von Arbin M, Kahan T, et al. Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. Cerebrovasc Dis. 2005;19:125-32. (Pubitemid 40278672)
48. Jacobs BL, Fornal CA. Serotonin and motor activity. Curr Opin Neurobiol. 1997;7:820-5. (Pubitemid 28052305)
49. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Neurosci Res. 2009;87:1037-45.
50. Li WL, Cai HH, Wang B, et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res. 2009;87:112-22.